Sex: U
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, COVID-19 immunisation, SARS-CoV-2 test, Vaccination failure
Clinical narrative: CONFIRMED CLINICAL VACCINATION FAILURE; CONFIRMED COVID-19 INFECTION; REVACCINATION WITH DIFFERENT COVID-19 VACCINE; This spontaneous report received from a health care professional by a other manufacturer (Pfizer Inc.) on 08-APR-2024 was received on 08-APR-2024 and concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. The patient's past medical history included: meniere's disease, appendicitis, and allergy. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 08-APR-2021 (Dose number in series:1) for covid-19 prophylaxis. Non-company suspect vaccine included: elasomeran ( batch number: 066F21A, form of admin, route of admin, and were not reported) dose was not reported, administered on 30-OCT-2021 (Dose number in series:2) for covid-19 prophylaxis. ; and tozinameran ( batch number: FP4554, batch number: GJ2524, batch number: HD9876, form of admin, route of admin, and were not reported) dose was not reported, administered on 31-MAR-2022 (Dose number in series:3), dose was not reported, administered on 07-OCT-2022 (Dose number in series:4), and dose was not reported, administered on 17-OCT-2023 (Dose number in series:5) for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. Concomitant medications included ascorbic acid/biotin/calcium carbonate/chromic chloride/cupric oxide/cyanocobalamin/ergocalciferol/folic acid/lycopene/magnesium oxide/manganese sulfate/nicotinamide/pantothenic acid/phytomenadione/potassium chloride/pyridoxine hydrochloride/retinol/riboflavin/thiamine mononitrate/vitamin e nos/zinc oxide, bupropion hydrochloride, cyanocobalamin, and triamcinolone acetonide. On an unspecified date, the patient experienced confirmed clinical vaccination failure (Dose number in series:5), confirmed covid-19 infection (Dose number in series:5), and revaccination with different covid-19 vaccine (Dose number in series:5). Patient took nirmatrelvir/ritonavir from 25-MAR-2024 afternoon until 30-MAR-2024 morning. After being symptom free from 26-MAR-2024 night until 02-APR-2024 morning (1 week). Test showed only a faint line after 15 minutes on 01-APR-2024 evening. Got a new head cold and scratchy throat / itchy lungs with first symptoms 02-APR-2024 evening and full effect 03-APR-2024 morning. Test showed a solid black line after just 2 seconds on 03-APR-2024 morning. The action taken with covid-19 vaccine ad26.cov2.s, elasomeran, and tozinameran was not applicable. The patient was recovering from confirmed covid-19 infection, and the outcome of revaccination with different covid-19 vaccine and confirmed clinical vaccination failure was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0:  Vaccination failure. The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event. Specifically: SPECIAL SITUATIONS. Therefore, this event is considered inconsistent with vaccine administration.